EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

NTBC and alkaptonuria


, : NTBC and alkaptonuria. American Journal of Human Genetics 63(3): 920-921

An alternative therapy for alkaptonuria that avoids the problem of gene localization is described. The signs and symptoms of alkaptonuria are thought to be caused by homogentisic acid (HA). The treatment involves the oral administration of the triketone herbicide 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) combined with some dietary restriction of phenylalanine and tyrosine. As triketone herbicides inhibit 4-hydroxyphenylpyruvate dioxygenase, which is the enzyme that produces HA, therapy with NTBC should prevent HA production.

Accession: 009919776

PMID: 9718357

DOI: 10.1086/302027

Download PDF Full Text: NTBC and alkaptonuria


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Phornphutkul, C.; Suwannarat, P.; Introne, W.; Bernardini, I.; Turner, M.; Heekin, R.D.; Kleta, R.; Gahl, W.A., 2003: Making the diagnosis of alkaptonuria Unusual skin findings in an alkaptonuria patient. American Journal of Human Genetics 73(5): 447, November

Arato, M.; Szijarto, A.; Vass, L., 1964: Some Data On The Clinical Picture Of Alkaptonuria. Modified Method For The Determination Of Alkaptonuria And Homogentisic Acid. Orvosi Hetilap 105: 1359-1361

Ranganath, L.R.; Milan, A.M.; Hughes, A.T.; Dutton, J.J.; Fitzgerald, R.; Briggs, M.C.; Bygott, H.; Psarelli, E.E.; Cox, T.F.; Gallagher, J.A.; Jarvis, J.C.; van Kan, C.; Hall, A.K.; Laan, D.; Olsson, B.; Szamosi, J.; Rudebeck, M.; Kullenberg, Törn.; Cronlund, A.; Svensson, L.; Junestrand, C.; Ayoob, H.; Timmis, O.G.; Sireau, N.; L.Q.an Sang, K-Hanh.; Genovese, F.; Braconi, D.; Santucci, A.; Nemethova, M.; Zatkova, A.; McCaffrey, J.; Christensen, P.; Ross, G.; Imrich, R.; Rovensky, J., 2016: Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment. Annals of the Rheumatic Diseases 75(2): 362-367

Anonymous, 2002: Nitisinone. Ntbc, Orfadin. Drugs in R&d 3(2): 139-140

Holme, E.; Lindstedt, S., 1998: Tyrosinaemia type I and NTBC -1,3-cyclohexanedione. In tyrosinaemia type I (McKusick 276700), fatal liver disease results either because of liver failure during infancy or early childhood or because of development of hepatocellular carcinoma during childhood or adolescence. This is caused by toxic...

Ahmad, S.; Teckman, J.H.; Lueder, G.T., 2002: Corneal opacities associated with NTBC treatment. PURPOSE: To describe a patient with hereditary tyrosinemia type I (HHT-I) treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) who developed corneal opacities. METHODS: A 14-month-old patient was diagnosed with HHT-I and b...

Ahmad, S.; Teckman, J.H.; Lueder, G.T., 2002: Corneal opacities associated with NTBC treatment. To describe a patient with hereditary tyrosinemia type I (HHT-I) treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) who developed corneal opacities. A 14-month-old patient was diagnosed with HHT-I and began treatment wit...

Jack, R.M.; Sadilkova, K.; Scott, C.R., 2003: Quantitation of NTBC in plasma of patients with tyrosinemia by LC-ESI-MS/MS. Journal of Inherited Metabolic Disease 26(Supplement 2): 198, September

Williams, R.E.; Lock, E.A., 2003: Does NTBC modulate D-serine-induced nephrotoxicity?. Toxicology Letters (Shannon) 144(Suppl 1): s96, September

Ros, J.; Vilaseca, M.A.; Lambruschini, N.; Mas, A.; Lindstedt, S.; Holme, E., 1999: NTBC as palliative treatment in chronic tyrosinaemia type I. Journal of Inherited Metabolic Disease 22(5): 665-666